West Island Brands - CEO, Boris Ziger
CEO, Boris Ziger
Source: Small Cap Power
  • West Island Brands (WIB) has completed the first tranche a non-brokered private placement for gross proceeds of $270,000.00
  • The company issued 1,080,000 units at a price of $0.25 per unit
  • The proceeds of private placement will be used for general working capital purposes
  • West Island Brands, formerly Matica Enterprises, is a company focused on the medical marijuana industry
  • Shares in West Island Brands Inc. (WIB) are unchanged, trading at C$0.59 per share at 1:15 pm EST

West Island Brands (WIB) has completed the first tranche a non-brokered private placement for gross proceeds of $270,000.00.

The company issued 1,080,000 units at a price of $0.25 per unit. Each unit is comprised of one common share and one common share purchase warrant. Each warrant will entitle the holder to purchase one common share at a price of $0.25 for a period of 24 months from the closing date of the offering.

The proceeds of the private placement will be used for general working capital purposes.

All securities purchased under this financing are subject to a four-month hold period.

Finder’s fees consisting of cash and broker warrants were paid in accordance with the policies of the CSE. Completion of the financing is subject to the acceptance of the CSE.

West Island Brands, formerly Matica Enterprises, is a company focused on the medical marijuana industry. Its projects include Dorval, Ionic mist, Hemmingford, and others.

West Island Brands Inc. (WIB) is unchanged on the day, trading at C$0.59 per share at 1:15 pm EST.

More From The Market Online

Tilray Brands seeks US$250M for U.S. cannabis expansion

Global cannabis stock Tilray Brands (TSX:TLRY) intends to raise up to US$250 million to fund its U.S. expansion plan.

The Market Online’s Weekly Cannabis Report – May 17, 2024

This international biopharmaceutical company revealed it has completed the retrospective observational real-world evidence study.

Avicanna finishes study of CBD cream’s use for rare skin disorder

Avicanna (TSX:AVCN) completes an observational study of its RHO Phyto-branded Ultra CBD topical cream on patients with epidermolysis bullosa.